Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

OCS-01

Small molecule · developed by Oculis

Phase 3 Most advanced trial (none active)
OCS Developer
1 Registered trials

What is OCS-01?

OCS-01 is a dexamethasone ophthalmic suspension, 1.5%, studied for inflammation and eye pain and for postoperative cataract.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Ophthalmology
Developer
Oculis (OCS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06128369 Phase 3 Inflammation Eye Pain Terminated OCS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Inflammation Eye PainPostoperative Cataract

More from Oculis

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OCS page.

Follow OCS, the company behind OCS-01

See OCS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OCS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.